Skip to main content

Evove

ApplicationWidnes, United KingdomFounded 2015· One of 381 Application companies tracked by AMPulse

Develops precision-engineered filtration and separation membranes using additive manufacturing and graphene-based coatings.

CEO / Founder
Chris Wyres
Team Size
11-50
Stage
Growth Stage
Total Funding
$22.6M
Latest Round
Strategic Investment
Key Investors
At One Ventures; AM Ventures; NPIF – Maven Equity Finance; Maven Capital Partners; Northern Powerhouse Investment Fund; One Small Planet; Kurita Water Industries

Technology & Products

Key Products

Enhance (enhanced membranes); Separonics (precision-engineered ceramic membranes)

Technological Advantage

Proprietary Separonics architecture enables higher throughput and selectivity; utilizes Lithoz LCM technology for high-precision ceramic manufacturing.

Differentiation

Value Proposition

Provides transformational productivity gains in selectivity and flux while reducing energy consumption and equipment lifetime compared to conventional membrane processes.

How They Differentiate

Unlike conventional membranes, Evove's AM-enabled Separonics membranes offer superior flux and selectivity through precise pore control and graphene integration.

Market & Competition

Target Customers

Lithium extraction companies, desalination plants, food and beverage manufacturers, industrial wastewater treatment facilities

Industry Verticals

Mining (Lithium/Vanadium extraction); Water Treatment; Desalination; Food & Beverage; Industrial Wastewater

Competitors

Traditional membrane manufacturers (e.g., DuPont, Suez/Veolia)

Growth & Milestones

Growth Metrics

Completed £5.7M funding round to accelerate growth; achieved 92% lithium recovery and 96.5% purity in demonstration trials

Major Milestones

Rebranded from G2O Water Technologies to Evove; Signed MOU with Saline Water Conversion Corporation for industrial desalination trials; Partnered with Northern Lithium for UK's first commercial-scale DLE plant

Notable Customers

Saline Water Conversion Corporation; Northern Lithium; Zelandez

Why this company matters

Evove develops precision-engineered filtration and separation membranes that combine additive manufacturing with graphene-based coatings. Founded in 2015 and based in Widnes, United Kingdom, the company targets the limitations of conventional membrane processes — namely the trade-off between flux and selectivity — by using 3D printing to create complex ceramic architectures that are impossible to produce with traditional methods.

The core technology is the Separonics platform, a proprietary ceramic membrane architecture manufactured using Lithoz LCM technology, a vat photopolymerization process for high-precision ceramics. Evove also applies graphene oxide coatings to enhance surface properties. The company's Enhance product line delivers these enhanced membranes for industrial applications. Key patents cover processes for monovalent ion extraction, lithium recovery from brines, and graphene oxide coating methods.

Evove serves the mining, water treatment, desalination, food and beverage, and industrial wastewater sectors. Target customers include lithium extraction companies, desalination plants, and industrial wastewater treatment facilities. Notable partners include the Saline Water Conversion Corporation for desalination trials, Northern Lithium for the UK's first commercial-scale direct lithium extraction plant, and Zelandez for modular DLE plants. In demonstration trials, Evove achieved 92% lithium recovery and 96.5% purity.

The company has raised $22.6 million from investors including At One Ventures, AM Ventures, and Kurita Water Industries, which also formed a strategic alliance for DLE. Evove competes against conventional membrane manufacturers such as DuPont and Suez/Veolia. Its key differentiator is the ability to precisely control pore geometry and integrate graphene coatings via additive manufacturing, enabling higher throughput and selectivity while reducing energy consumption. A key open question is whether the AM-enabled membranes can scale cost-effectively to compete with established flat-sheet and spiral-wound membrane production at industrial volumes.